Navigation Links
Relief Is Available for Cancer Patients Suffering from Radiation Therapy-Related Nausea
Date:4/19/2009

A recently released study led by Joseph A. Roscoe, Ph.D. of the University of Rochester and funded by the American Cancer Society and the National Cancer Society concludes that Sea-Band Accupressure Wristbands are effective in reducing nausea associated with radiation-therapy used to treat cancer patients. The non intrusive wristbands place light pressure on the P6 acupressure point on each wrist. This all natural and easy to administer remedy is safe for children and adults.

Newport, RI (PRWEB) April 19, 2009 -- A just released study, conducted by Joseph A. Roscoe, Ph.D. of the University of Rochester's James P. Wilmot Cancer Center in Rochester, NY indicates that similar to previous experimental research conducted, Sea-Band Wristbands are effective in controlling nausea in patients experiencing radiation therapy-related nausea. The study reports that "nausea for cancer treatments, once it occurs, is often very difficult to control and yet these simple bands were effective in that effort. It is a low cost, non intrusive, safe adjunct to standard antiemetics that has great patient acceptance." The use of Sea-Bands, as they are commonly called, causes no side effects and they are readily available over the counter at pharmacies and drug stores.

This independent study was partially funded by the American Cancer Society and the National Cancer Society.

In 2004, the FDA approved Sea-Band Wristbands for use in preventing nausea and vomiting. Sea-Band Wristbands are the only FDA approved acupressure treatment of its kind in the United States. Long accepted in Eastern medicine and more recently in Europe as a cure for nausea and vomiting, acupressure and more specifically the pressure point P6, located between the two major tendons on the inside of the arm, approximately 2 inches below the crease of the wrist, is where Sea-Band Wristbands places light steady pressure via a p
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. Experimental Antidepressants Offer Faster Relief
2. Big Relief for Tiny Itch Mites Found in All Natural Spray Remedy
3. AmeriCares Airlifts Relief to Nicaragua and Honduras
4. Vitamin Relief Brings Needed Nutrition to School District Resurrecting After Katrina
5. The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique
6. ThermoTx Introduces New Mobile Stimulation (TENS) Product Line for On the Go Therapy and Pain Relief
7. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
8. AmeriCares and International Medical Corps Airlift Relief for Cholera Outbreak In Iraq
9. MyoMed Launches Flash Virtual Tour of Toxin-Free Pain Relief
10. Friends of WFP Welcomes World Hunger Relief Week
11. Nicotine, Chili Peppers Offer Post-Surgery Pain Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... been significant scientific advances in the field of blood ... understanding of how certain diseases progress in order to ... best care. Research presented today at the 51st Annual ... induction therapies for managing multiple myeloma, the importance of ...
(Date:12/5/2009)... Is Most Challenging-- ,, PHILADELPHIA and NEW ... genes, dubbed partner genes, that fuse with another gene ... By more accurately defining specific partner genes, researchers expect ... treatments. ,, Oncologists also aim to use this ...
(Date:12/5/2009)... , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor ... the knot, since research has shown that never-married adults have ... something wrong with those who go it alone anyway? , ... measures shows that never-married people aged 40 and up can ...
(Date:12/5/2009)... by the National Association of Certified Professional Midwives ... for Midwifery (CfM), International Center for Traditional Childbearing ... the Midwifery Education Accreditation Council (MEAC). To ... Campaign to secure federal recognition of CPMs language ...
(Date:12/4/2009)... Inc. (NYSE: CRE ) ("Care" or the "Company") ... of $0.17 per share of common stock. The dividend is ... December 14, 2009. ,, About Care Investment ... investment and finance company investing in healthcare-related real estate and commercial ...
Breaking Medicine News(10 mins):Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
... Park, Michigan-based Image,One owners, Joel Pearlman and Rob ... raising awareness and funding for autism.,Through the sale ... established goal of,raising $1,000,000 by contributing five percent ... and issues. Founder Rob,Dube made the announcement., ...
... Ga., July 7 Athens Regional Medical Center and,Blue ... the signing,of a multi-year contract, enabling Athens Regional to ... has had a PPO contract with,Athens Regional for many ... and POS members throughout,Georgia will be able to gain ...
... NEW YORK, July 7 Many people ... complication associated with diabetes -- serious gum,disease. ... health and diabetes., Listen to ... Registered journalists can access video, audio, ...
... Mothers and fathers of twins conceived either spontaneously or ... symptoms after delivery and one year later than do ... the 24th annual meeting of the European Society of ... , However, the mothers of ART twins had fewer ...
... at 2008 Convention, BALTIMORE, July 7 ... cash awards to individuals and,organizations that have made ... blind into society on a basis of equality. ... in the blindness,field at the National Federation of ...
... ADL ), a,leading vertically integrated bio-pharmaceutical company ... the US Food and Drug Administration (FDA),has issued ... predicate,device and granted clearance to market the AMDL-ELISA ... for monitoring patients who have been,previously diagnosed with ...
Other Medicine News:Health News:TonerForAutism.com Strives to Fund Autism Research Through Online Sales 2Health News:Blue Cross and Blue Shield of Georgia and Athens Regional Medical Center Announce New HMO/POS Contract 2Health News:Parents of twins report more mental health symptoms than parents of singletons 2Health News:Parents of twins report more mental health symptoms than parents of singletons 3Health News:Parents of twins report more mental health symptoms than parents of singletons 4Health News:National Federation of the Blind Awards $100,000 2Health News:FDA Grants AMDL Clearance to Market the AMDL-ELISA DR-70(R) (FDP) Blood Test for Monitoring Colorectal Cancer 2Health News:FDA Grants AMDL Clearance to Market the AMDL-ELISA DR-70(R) (FDP) Blood Test for Monitoring Colorectal Cancer 3
(Date:12/4/2009)... Inc. (NYSE: HSP ), a leading global ... launch of its next-generation 50 mL and 100 mL ... now offers a complete size range (50 mL to ... The launch of the 50 mL and 100 mL ...
(Date:12/4/2009)... 4 Axsun Technologies, Inc., a wholly-owned subsidiary of ... initial development and successful testing of a novel integrated ... this proprietary optical engine design raises the bar on ... for swept source OCT light sources. This approach ...
(Date:12/4/2009)... Dec. 4 Drs. Neal Shore and E. David ... the additional analysis of secondary end points of biochemical ... FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in ... Prostate cancer patients who received FIRMAGON 240/80 mg/month ...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Online Store Offers Affordable Digital Hearing Aids For Baby Boomers 48986 1Online Store Offers Affordable Digital Hearing Aids For Baby Boomers 48986 2Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World 48984 1Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World 48984 2Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World 48984 3A STAR scientists invent the worlds only controllable molecule gear of minuscule size of 1 2nm 12637 1A STAR scientists invent the worlds only controllable molecule gear of minuscule size of 1 2nm 12637 2
... into phase IIb study, called POLI 1 -, ... Roche,s new,investigational drugs for chronic hepatitis C virus ... in combination with,PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), ... for the Study of the,Liver Disease (AASLD) meeting, ...
... IDM-2101 showed an improvement in median survival vs. ... parallel external controls -, ... ) today announced updated results from the Phase 2 study of,its ... specific cytotoxic T lymphocyte (CTL) responses,and showed a positive survival trend ...
Other Medicine Technology:Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 2Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 3Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 4Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 5Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 6Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 7IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 2IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 3IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: